

Lubos Petruzelka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4500832/publications.pdf>

Version: 2024-02-01

118
papers

9,536
citations

101543

36
h-index

38395

95
g-index

126
all docs

126
docs citations

126
times ranked

13466
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet, The</i> , 2013, 381, 805-816.	13.7	1,664
2	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	13.7	1,487
3	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018, 19, 27-39.	10.7	717
4	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4594-4600.	1.6	553
5	Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. <i>Lung Cancer</i> , 2004, 46, 87-98.	2.0	400
6	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. <i>Lancet Oncology, The</i> , 2011, 12, 1101-1108.	10.7	356
7	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01). <i>J Clin Oncol</i> , 2010, 28, 467-474.	10.7	318
8	Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. <i>Journal of Clinical Oncology</i> , 2008, 26, 5569-5575.	1.6	299
9	Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. <i>Trends in Cancer</i> , 2017, 3, 391-406.	7.4	262
10	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt337-djt337.	6.3	218
11	Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer — Results of the eLEcTRA trial. <i>Breast</i> , 2012, 21, 27-33.	2.2	195
12	Third consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2009, 20, 1771-1785.	1.2	178
13	Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). <i>Annals of Oncology</i> , 2011, 22, 1154-1163.	1.2	165
14	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. <i>Annals of Oncology</i> , 2009, 20, 1489-1498.	1.2	163
15	Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. <i>Lung Cancer</i> , 2003, 41, 321-331.	2.0	153
16	MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017, 18, 192-201.	10.7	138
17	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	1.6	130
18	Novel Therapeutic Targets in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1601-1612.	1.1	127

#	ARTICLE	IF	CITATIONS
19	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. <i>Lancet Oncology</i> , The, 2013, 14, 125-133.	10.7	107
20	Receptor for Advanced Glycation End Products (RAGE) Soluble Form (sRAGE) and Gene Polymorphisms in Patients with Breast Cancer. <i>Cancer Investigation</i> , 2007, 25, 720-725.	1.3	100
21	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. <i>Annals of Oncology</i> , 2012, 23, 1214-1222.	1.2	91
22	Second consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2007, 18, 215-225.	1.2	86
23	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	2.8	84
24	Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study. <i>Breast Journal</i> , 2009, 15, 461-467.	1.0	79
25	Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. <i>Lancet Oncology</i> , The, 2012, 13, 420-432.	10.7	61
26	High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. <i>Breast Cancer Research</i> , 2005, 7, R728-36.	5.0	59
27	Dietary habits and lung cancer risk among non-smoking women. <i>European Journal of Cancer Prevention</i> , 2004, 13, 471-480.	1.3	58
28	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1230-1239.	10.7	55
29	Raman spectroscopy at different excitation wavelengths (1064, 785 and 532 nm) as a tool for diagnosis of colon cancer. <i>Journal of Raman Spectroscopy</i> , 2014, 45, 903-911.	2.5	53
30	Lung Cancer Risk among Czech Women: A Case-Control Study. <i>Preventive Medicine</i> , 2002, 34, 436-444.	3.4	52
31	Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. <i>British Journal of Cancer</i> , 2006, 95, 788-793.	6.4	52
32	Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. <i>Lung Cancer</i> , 2003, 41, 283-293.	2.0	49
33	Plasma Fatty Acid Composition in Patients with Pancreatic Cancer: Correlations to Clinical Parameters. <i>Nutrition and Cancer</i> , 2012, 64, 946-955.	2.0	43
34	Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. <i>Cancer</i> , 2011, 117, 4606-4616.	4.1	39
35	Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. <i>Neoplasia</i> , 2016, 63, 269-73.	1.6	39
36	Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. <i>Annals of Oncology</i> , 2003, 14, 1383-1390.	1.2	38

#	ARTICLE	IF	CITATIONS
37	KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. <i>Melanoma Research</i> , 2005, 15, 251-256.	1.2	38
38	Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. <i>Clinical Trials</i> , 2009, 6, 272-287.	1.6	37
39	Consensus on Medical Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 1-7.	2.5	36
40	Breast cancer risk assessment in the Czech female population – an adjustment of the original Gail model. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 29-35.	2.5	34
41	The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 165-167.	2.5	31
42	Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 695-700.	2.5	31
43	Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer. <i>Cancer Biomarkers</i> , 2018, 21, 869-874.	1.7	30
44	Gemcitabine/carboplatin in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2002, 38, 33-36.	2.0	27
45	Analysis of human blood plasma and hen egg white by chiroptical spectroscopic methods (ECD, VCD). <i>Talanta</i> , 2017, 167, 107-114.	3.7	27
46	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. <i>British Journal of Cancer</i> , 2014, 111, 2051-2057.	6.4	26
47	The minimizing of fluorescence background in Raman optical activity and Raman spectra of human blood plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 1335-1342.	3.7	26
48	Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer. <i>International Journal of Biological Markers</i> , 2019, 34, 292-301.	1.8	25
49	Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer. <i>Oncology Letters</i> , 2019, 18, 6284-6292.	1.8	24
50	Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. <i>Lung Cancer</i> , 1998, 22, 243-250.	2.0	23
51	Lessons from the Iressa™ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. <i>British Journal of Cancer</i> , 2003, 89, S19-S23.	6.4	22
52	Mutations of the BRCA1 Gene in Hereditary Breast and Ovarian Cancer in the Czech Republic. <i>Medical Principles and Practice</i> , 2003, 12, 23-29.	2.4	22
53	Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers. <i>Cancers</i> , 2019, 11, 738.	3.7	22
54	Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. <i>Supportive Care in Cancer</i> , 2005, 13, 760-762.	2.2	21

#	ARTICLE	IF	CITATIONS
55	The potential of chiroptical and vibrational spectroscopy of blood plasma for the discrimination between colon cancer patients and the control group. <i>Analyst, The</i> , 2015, 140, 2287-2293.	3.5	21
56	Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. <i>Ecological Management and Restoration</i> , 2010, 23, 160-167.	0.4	20
57	Activity of fulvestrant in HER2-overexpressing advanced breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1246-1253.	1.2	20
58	Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer.. <i>Neoplasma</i> , 2015, 62, 470-477.	1.6	20
59	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 149-155.	2.5	16
60	Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. <i>Targeted Oncology</i> , 2017, 12, 89-95.	3.6	15
61	A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7071-7078.	7.0	14
62	Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 159-174.	1.8	14
63	Large expansion of morphologically heterogeneous mammary epithelial cells, including the luminal phenotype, from human breast tumours. <i>Breast Cancer Research and Treatment</i> , 2002, 71, 219-235.	2.5	13
64	Abstract S1-4: Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. <i>Cancer Research</i> , 2012, 72, S1-4-S1-4.	0.9	13
65	Report on the first patient group of the phase I BNCT trial at the LVR-15 reactor. <i>International Congress Series</i> , 2004, 1259, 27-32.	0.2	11
66	Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy “ results from an expanded access programme. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 132-133.	2.2	11
67	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 295-306.	2.5	11
68	Predicting axillary sentinel node status in patients with primary breast cancer.. <i>Neoplasma</i> , 2013, 60, 334-342.	1.6	11
69	Apoptosis “ associated genes and their role in predicting responses to neoadjuvant breast cancer treatment. <i>Medical Science Monitor</i> , 2012, 18, BR60-BR67.	1.1	10
70	Serum Adiponectin Relates to Shortened Overall Survival in Men with Squamous Cell Esophageal Cancer Treated with Preoperative Concurrent Chemoradiotherapy: A Pilot Study. <i>Medical Science Monitor</i> , 2014, 20, 2351-2357.	1.1	10
71	Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 581-586.	1.8	9
72	Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy. <i>Neoplasma</i> , 2014, 61, 90-98.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: A study of 55 cases. <i>Molecular Medicine Reports</i> , 2014, 10, 2669-2674.	2.4	9
74	Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. <i>Targeted Oncology</i> , 2015, 10, 557-563.	3.6	9
75	Plasma Phosphatidylcholines Fatty Acids in Men with Squamous Cell Esophageal Cancer: Chemoradiotherapy Improves Abnormal Profile. <i>Medical Science Monitor</i> , 2016, 22, 4092-4099.	1.1	8
76	Anthracycline antibiotics derivate mitoxantroneâ€”Destructive sorption and photocatalytic degradation. <i>PLoS ONE</i> , 2018, 13, e0193116.	2.5	8
77	<p>Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5365-5372.	1.9	8
78	Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers. <i>Neoplasma</i> , 2010, 57, 280-285.	1.6	7
79	PET/CT significance for planning radiotherapy of head and neck cancer. <i>Neoplasma</i> , 2012, 59, 536-540.	1.6	7
80	Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients. <i>Neoplasma</i> , 2015, 62, 259-268.	1.6	6
81	Ex Vivo Vibration Spectroscopic Analysis of Colorectal Polyps for the Early Diagnosis of Colorectal Carcinoma. <i>Diagnostics</i> , 2021, 11, 2048.	2.6	5
82	Novel biochemical markers for non-invasive detection of pancreatic cancer. <i>Neoplasma</i> , 2022, 69, 474-483.	1.6	5
83	Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer. <i>Anti-Cancer Drugs</i> , 2003, 14, S7-S12.	1.4	4
84	Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neuâ€” positive advanced breast cancer: results of the CECOG LaVie trial. <i>BMC Cancer</i> , 2016, 16, 121.	2.6	4
85	Molecular pathological predictive diagnostics in a patient with nonâ€”small cell lung cancer treated with crizotinib therapy: A case report. <i>Oncology Letters</i> , 2017, 14, 7545-7548.	1.8	4
86	Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. <i>Targeted Oncology</i> , 2020, 15, 193-201.	3.6	4
87	The protective effect of pyrimidine nucleosides on human HaCaT keratinocytes treated with 5-FU. <i>Anticancer Research</i> , 2015, 35, 1303-10.	1.1	4
88	POSTOPERATIVE RADIOCHEMOTHERAPY WITH WEEKLY CISPLATIN IN PATIENTS WITH HEAD AND NECK CANCER SINGLE-INSTITUTION OUTCOME ANALYSIS. <i>Neoplasma</i> , 2012, 59, 129-136.	1.6	3
89	Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. <i>Anticancer Research</i> , 2015, 35, 3455-61.	1.1	3
90	Local Treatment of Hand-Foot Syndrome with Uridine/Thymidine:In VitroAppraisal on a Human Keratinocyte Cell Line HaCaT. <i>Scientific World Journal</i> , The, 2012, 2012, 1-6.	2.1	2

#	ARTICLE	IF	CITATIONS
91	Breast cancer characteristics“Comparison of preoperative and postoperative values. Pathology Research and Practice, 2013, 209, 433-440.	2.3	2
92	Modified FOLFIRINOX in the treatment of pancreatic cancer “ efficiency and toxicity. Gastroenterologie A Hepatologie, 2016, 70, 413-417.	0.1	2
93	http://www.linkos.cz/klinicka-onkologie-journal/search-for-articles/skupina/a/zobrazit/ids/4854/ . Klinicka Onkologie, 2015, 28, 4S82-4S85.	0.3	2
94	Role of Taxanes. Breast Cancer Research and Treatment, 2003, 81, 17-24.	2.5	1
95	Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+). Lung Cancer, 2012, 77, S25.	2.0	1
96	Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study. Molecular and Clinical Oncology, 2016, 5, 161-164.	1.0	1
97	Molecular analysis of JAK2 gene in patients with triple negative breast cancer in relation to disease prognosis “ a pilot study. Breast, 2017, 32, S46.	2.2	1
98	5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line. Prague Medical Report, 2017, 118, 128-138.	0.8	1
99	Inclusion of the FOLFIRINOX regimen in the treatment algorithm for metastatic pancreatic cancer “ first experience. Gastroenterologie A Hepatologie, 2014, 68, 436-440.	0.1	1
100	Immunomodulation with Î²-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer. Immunotherapy, 2022, 14, 31-40.	2.0	1
101	In vivo dosimetry with the use of silicon photodiodes. Journal of Radioanalytical and Nuclear Chemistry, 1988, 127, 1-5.	1.5	0
102	The comparative randomised study of adjuvant therapy of breast cancer patients with tamoxifen versus tamoxifen plus chemotherapy. European Journal of Cancer, 1999, 35, S209.	2.8	0
103	Oxidative stress products and soluble adhesion molecules in patients with breast cancer. European Journal of Cancer, Supplement, 2004, 2, 104.	2.2	0
104	Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. European Journal of Cancer, Supplement, 2004, 2, 105.	2.2	0
105	P-978 Gefitinib (ZD 1839, Iressa®) in treatment of advanced non-small cell lung cancers “ one institutional experience on an expanded access program. Lung Cancer, 2005, 49, S377.	2.0	0
106	P2 Receptor for advanced glycation end products (RAGE) “ Soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Breast, 2007, 16, S13.	2.2	0
107	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. Breast, 2011, 20, S45.	2.2	0
108	A multicentre prospective study on pemetrexed in the second line chemotherapy of non small cell lung cancer. Data from routine clinical practice. Lung Cancer, 2012, 77, S33.	2.0	0

#	ARTICLE	IF	CITATIONS
109	Concurrent chemoradiotherapy in locally advanced non-small cell lung cancerâ€”Prognostic factors and reasons for treatment failure in group of patients 1996â€”2008. Lung Cancer, 2012, 77, S42.	2.0	0
110	Neoadjuvant Trastuzumab in HER2+ early breast cancer patients â€” one clinic experience. Breast, 2017, 32, S78.	2.2	0
111	Abstract C68: Transforming growth factor-beta and vascular endothelial growth factor are enhanced in plasma of breast cancer patients resistant to hormone therapy. , 2011, , .		0
112	Abstract 5382: Vascular endotelial growth factor and transforming growth factor-beta are enhanced in plasma of breast cancer patients resistant to endocrine therapy. , 2012, , .		0
113	Abstract B9: Abnormalities in cellular and humoral immunity in breast cancer patients resistant to endocrine therapy.. , 2013, , .		0
114	Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.. , 2013, , .		0
115	New perspectives on pharmacotherapy in the algorithm of colorectal cancer liver metastases management. Gastroenterologie A Hepatologie, 2014, 68, 424-429.	0.1	0
116	Abstract 2406: Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers. , 2015, , .		0
117	Abstract P6-04-12: Immunoprofile of TIL, genetics of Fc receptor gama and apoptosis activation in patients with Her2-positive breast cancer â€” Pilot study. , 2016, , .		0
118	Immunomonitoring in patients with stage II and III colon cancer.. Journal of Clinical Oncology, 2017, 35, e23038-e23038.	1.6	0